Warner-Lambert conducting clinicals for antigingivitis toothpaste.
This article was originally published in The Rose Sheet
Executive Summary
WARNER-LAMBERT LISTERINE TOOTHPASTE ANTIPLAQUE/ANTIGINGIVITIS INDICATIONS would require a six-month study in humans, FDA's Nonprescription Drugs Advisory Committee's Dental Plaque Subcommittee concluded following a Warner-Lambert presentation on a proposed testing protocol. Based on the subcommittee's prior conclusion that Listerine Antiseptic Mouthwash's essential oil combination -- menthol, thymol, methyl salicylate and eucalyptol -- is a safe and effective antiplaque and antigingivitis agent in concentrations of 51.7 mg/dose ("The Rose Sheet" Nov. 3, 1997, p. 16), the NDAC group determined at its May 27 meeting that one additional trial in humans would be sufficient to establish the ingredient combination's safety and efficacy in a new toothpaste dosage form.
You may also be interested in...
Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
The antigingivitis/antiplaque monograph should require that products containing a fixed combination of the essential oils menthol, thymol, methyl salicylate and eucalyptol be tested with both in vitro and in vivo test methods, Pfizer Consumer Healthcare maintains
Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
The antigingivitis/antiplaque monograph should require that products containing a fixed combination of the essential oils menthol, thymol, methyl salicylate and eucalyptol be tested with both in vitro and in vivo test methods, Pfizer Consumer Healthcare maintains
OTC "feedback" meeting
Warner-Lambert scheduled to meet with FDA to discuss the regulatory pathway for producing a product that combines the anticaries and oral health monographs. The meeting will be held Oct. 8 at 10:00 a.m. in Rockville, Md. W-L presented a proposed testing protocol for a Listerine antiplaque/antigingivitis toothpaste before FDA's Dental Plaque Subcommittee last year (1"The Rose Sheet" June 1, 1998, p. 1)